Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
6.17
+0.22 (3.70%)
At close: Sep 4, 2026, 4:00 PM EDT
6.05
-0.12 (-1.94%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $1.63M in the quarter ending June 30, 2026, a decrease of -8.33%. This brings the company's revenue in the last twelve months to $8.22M, down -51.05% year-over-year. In the year 2025, Aclaris Therapeutics had annual revenue of $7.83M, down -58.19%.
Revenue (ttm)
$8.22M
Revenue Growth
-51.05%
P/S Ratio
110.50
Revenue / Employee
$112,589
Employees
73
Market Cap
908.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.83M | -10.89M | -58.19% |
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
| Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
| Dec 31, 2017 | 1.68M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 450.89M |
| Rigel Pharmaceuticals | 276.79M |
| Theravance Biopharma | 104.31M |
| Crescent Biopharma | 11.88M |
| Silence Therapeutics | 615.00K |
ACRS News
- 1 day ago - Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 3 days ago - Canaccord starts Aclaris with Buy on ‘sizeable’ U.S. opportunities - TheFly
- 3 days ago - Aclaris Therapeutics initiated with a Buy at Canaccord - TheFly
- 4 weeks ago - Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib - TheFly
- 4 weeks ago - Aclaris Therapeutics files automatic mixed securities shelf - TheFly
- 4 weeks ago - Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - GlobeNewsWire
- 4 weeks ago - Aclaris Therapeutics reports Q2 EPS (15c), consensus (16c) - TheFly
- 4 weeks ago - Aclaris Therapeutics Earnings release: Q2 2026 - Filings